Qiagen Discloses It Spent up to $181.7M on Recent Acquisitions | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen made three acquisitions in April and May for up to $181.7 million, it disclosed in a document filed yesterday with the US Securities and Exchange Commission.

In its Form 10-Q Qiagen said that the acquisitions included the remaining 60 percent of Scandinavian Gene Synthesis that it didn't already own, and AmniSure International. Qiagen did not provide details on its third acquisition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.